- Home
- IMAB vs PFX Comparison
IMAB vs PFX Comparison
Compare IMAB & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- PFX
- Stock Information
- Founded
- IMAB 2014
- PFX 2010
- Country
- IMAB United States
- PFX United States
- Employees
- IMAB N/A
- PFX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- PFX Finance: Consumer Services
- Sector
- IMAB Health Care
- PFX Finance
- Exchange
- IMAB Nasdaq
- PFX Nasdaq
- Market Cap
- IMAB 83.8M
- PFX 99.3M
- IPO Year
- IMAB 2020
- PFX N/A
- Fundamental
- Price
- IMAB $1.07
- PFX $49.87
- Analyst Decision
- IMAB Strong Buy
- PFX
- Analyst Count
- IMAB 3
- PFX 0
- Target Price
- IMAB $8.00
- PFX N/A
- AVG Volume (30 Days)
- IMAB 682.1K
- PFX 2.3K
- Earning Date
- IMAB 03-13-2025
- PFX 02-06-2025
- Dividend Yield
- IMAB N/A
- PFX N/A
- EPS Growth
- IMAB N/A
- PFX N/A
- EPS
- IMAB N/A
- PFX 9.13
- Revenue
- IMAB $3,313,984.00
- PFX $22,181,598.00
- Revenue This Year
- IMAB N/A
- PFX $4.64
- Revenue Next Year
- IMAB N/A
- PFX N/A
- P/E Ratio
- IMAB N/A
- PFX $5.46
- Revenue Growth
- IMAB N/A
- PFX 10.18
- 52 Week Low
- IMAB $0.84
- PFX $42.50
- 52 Week High
- IMAB $2.08
- PFX $51.50
- Technical
- Relative Strength Index (RSI)
- IMAB 55.17
- PFX 56.22
- Support Level
- IMAB $1.00
- PFX $48.49
- Resistance Level
- IMAB $1.20
- PFX $49.50
- Average True Range (ATR)
- IMAB 0.12
- PFX 0.50
- MACD
- IMAB 0.02
- PFX -0.13
- Stochastic Oscillator
- IMAB 40.97
- PFX 59.82
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About PFX PhenixFIN Corporation
PhenixFIN Corp formerly Medley Capital Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.